Skip to content

Median effective dose of remimazolam combined with remifentanil for moderate sedation gastroscopy in obese patients

Median effective dose of remimazolam combined with remifentanil for moderate sedation gastroscopy in obese patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070089
Enrollment
Unknown
Registered
2023-04-01
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroscopy

Interventions

Remimazolam Group:Remimazolam

Sponsors

Department of Anesthesiology, Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-65 years; (2) ASA physical status I or II; (3) BMI=30 kg/m2 (4) Undergo painless gastroscopy; (5) It is expected that the operation time of gastroscopy will not exceed 15min (6) Be willing to cooperate with this research

Exclusion criteria

Exclusion criteria: (1) Endoscopic diagnosis and treatment techniques that require complex procedures (such as cholangiopancreatography, endoscopic ultrasonography, endoscopic mucosal resection, endoscopic submucosal dissection, and oral endoscopic muscle disconnection); (2) After admission, the patient's SpO2 = 95%, systolic blood pressure = 180mmHg, and/or diastolic blood pressure = 110mmHg; (3) Was clearly diagnosed as obstructive sleep apnea syndrome; (4) Persons who are known to be allergic to or have contraindications to opioids and their relievers, benzodiazepines and their relievers; (5) Taking benzodiazepines every day within a month or intermittently within the past three months; (6) Severe respiratory and cardiovascular system diseases and liver and kidney function coagulation insufficiency; (7) Persons with mental system diseases, long-term history of taking psychotropic drugs, and cognitive impairment; (8) Have a history of drug abuse, drug abuse, and alcohol abuse within 2 years before the screening period begins; (9) Has participated in other researchers.

Design outcomes

Primary

MeasureTime frame
The score of MOAA/S after induction;

Secondary

MeasureTime frame
The incidience of SpO2<95%;The incidience of SpO2<90%;The patient's satisfaction;The endoscopist's satisfaction;The duration of gastroscopy;The duration of revival;hemodynamics;

Countries

China

Contacts

Public ContactJia Mengxing

Department of Anesthesiology, Affiliated Hospital of Xuzhou Medical University

xzmu_jiamengxing@126.com+86 15895238016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026